RANCHO SANTA MARGARITA, Calif., May 01, 2018 -- Melissa, a leading provider of global contact data quality and identity verification solutions, today announced Druginator, a new, tightly targeted element of its comprehensive data quality toolset to clean, harmonize, and connect disparate content sources for clinical insight and discovery. As part of the Melissa Informatics array of data quality solutions, datasets, and knowledge engineering resources, Druginator checks and validates millions of pharmaceutical drug names, variants, dosages, and spellings in real-time, against a comprehensive drug lexicon aligned with industry standards. The Melissa Informatics team will feature Druginator at the Bio-IT World Conference and Expo, #BioIT18, booth M634, May 15-17, 2018, at the Seaport World Trade Center in Boston.
Druginator provides a web-based UI for checking, verifying, and enriching drug names or lists of drugs, as well as web service APIs for drug data. Diverse, misspelled, and otherwise “dirty” drug information, whether from electronic medical records (EMRs) or from pharmaceutical dictionaries, studies, or public sources, is checked and reported with standardized “preferred terms” to become instantly usable for pharmaceutical and healthcare informatics. This provides an efficient resource to help researchers and clinicians check, verify, and normalize drug terms to reduce costs, increase accuracy, and improve research and patient outcomes.
Aligning with the industry goal to advance medicine through optimized data, Druginator harnesses the power of formal semantic technologies to apply machine reasoning to infer new concepts, linkages, and corrections to data about drugs. Future versions of Druginator will harmonize other types of mission-critical clinical data, such as diseases, genes, and proteins.
“Disconnected data is messy and not contextualized, slowing mission-critical goals such as FDA approval, time to market and understanding real-world use patterns for drugs. For example, a single medical records database was shown to contain nearly 200 different variations, spellings, and compounds of just one drug commonly used in the treatment of Parkinson’s disease. Discrepancies like this can have crucial implications on patient analyses, treatments, and treatment outcomes,” said Daniel Kha Le, vice president, Melissa Informatics.
Melissa Informatics’ drug, patient, disease, gene, protein, metabolic, and consumer-centered ontologies allow clinicians to easily refocus their research, tapping into different contextual insights based on the same data sets. With Druginator, drug names are checked and verified against a database of drug standard names, to meet FDA, UMLS and other terminology standards as required. Druginator’s append feature searches variations, alternate names, combination drugs, and available dosages to deliver comprehensive intelligence about your checked and verified drug. Autocompletion capabilities accelerate data entry, ensure standardization, and reduce clerical errors by offering an auto-populated list of variants matched in real-time.
Druginator is part of Melissa Informatics’ Sentient™ platform – semantic technologies that can be applied horizontally to accommodate the broad spectrum of pharmaceutical and clinical data harmonization and enrichment needs, integrating content across virtually any data format or terminology regardless of its original source. To connect with Melissa Informatics or members of Melissa’s global intelligence team, visit www.Melissa.com or call 1-800-MELISSA.
About Melissa
Since 1985, Melissa has specialized in global intelligence solutions to help organizations unlock accurate data for a more compelling customer view. More than 10,000 clients worldwide in arenas such as retail, education, healthcare, insurance, finance, and government, rely on Melissa for full spectrum data quality and ID verification software, including data matching, validation, and enhancement services to gain critical insight and drive meaningful customer relationships. For more information or free product trials, visit www.Melissa.com or call 1-800-MELISSA (635-4772).
About Melissa Informatics
Melissa Informatics extends the capabilities of Melissa’s global intelligence software and services to support world leaders in life sciences, biotechnology, pharmaceutical, and medical industries by harnessing the entire data lifecycle for business, pharmaceutical and clinical data. Our software and services bring data quality and machine reasoning together for insight and discovery by intelligently cleaning, connecting, and harmonizing multiple sources to offer interoperable data. Melissa Informatics reduces time and cost to benefit from clean, richly connected data. Revealing deeper data relationships from complex, dynamic data through machine reasoning operations, Melissa Informatics ensures the most reliable information in mission critical financial services, healthcare, and life science informatics. For more information or free product trials, visit www.Melissa.com/informatics or call 1-800-MELISSA (635-4772).
| Greg Brown | Jackie Zerbst | ||||
| Vice President, Marketing | MPowered Public Relations | ||||
| Melissa | [email protected] | ||||
| [email protected] | (714) 998-3448 | ||||
| (800) 635-4772 x1130 |


Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 



